Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress
- Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY 11794-5200
-
Edited by Louis J. Ignarro, University of California School of Medicine, Los Angeles, CA (received for review August 19, 2005)
Abstract
Nitric oxide-donating aspirin (NO-ASA) is a promising chemoprevention agent against colon cancer and other cancers. It consists
of traditional ASA to which a NO-releasing moiety is bound through a spacer. NO-ASA inhibits colon cancer cell growth several
hundred times more potently than does ASA. In Min mice, NO-ASA inhibited intestinal carcinogenesis without affecting cell proliferation. Thus, we examined whether NO-ASA's
most important cell kinetic effect is the induction of apoptosis. After confirming induction of apoptosis in Min mice, we studied the underlying mechanism in human colon adenocarcinoma cells. NO-ASA's spacer formed a conjugate with glutathione,
depleting glutathione stores. This induced oxidative stress (increased intracellular levels of peroxides and
) leads to apoptosis by activating the intrinsic apoptosis pathway. NO-ASA disrupted adherens junctions by inducing cleavage
of β- and γ-catenin, resulting in cell detachment. NO-ASA inhibited Wnt signaling by a dual mechanism: at low concentrations
it blocked the formation of β-catenin/Tcf complexes (dominant mechanism), and at higher concentrations it also cleaved β-catenin.
These findings provide a mechanism of action by a potent chemopreventive agent, underscore the significance of these pathways
in regulating cell death in the context of cancer chemoprevention, and present a paradigm for developing agents with enhanced
cancer cell growth inhibitory properties.
Footnotes
-
↵ * To whom correspondence should be addressed. E-mail: basil.rigas{at}sunysb.edu.
-
Author contributions: J.G. and B.R. designed research; J.G. and X.L. performed research; J.G., X.L., and B.R. analyzed data; and J.G. and B.R. wrote the paper
-
Conflict of interest statement: No conflicts declared.
-
This paper was submitted directly (Track II) to the PNAS office.
-
Abbreviations: ASA, aspirin; NO-ASA, NO-donating aspirin; DEVD-FMK, Asp-Glu-Val-Asp fluoromethyl ketone; Z-VAD-FMK, benzyloxycarbonyl-Val-Ala-Asp-FMK; DHE, dihydroethidium; H2DCFDA, 2′,7′-dichlorofluorescine diacetate; GSH, glutathione; ROS, reactive oxygen species; NAC, N-acetylcysteine; PI, propidium iodide; BSO, dl-buthionine (S,R)-sulfoximine.
- Copyright © 2005, The National Academy of Sciences





